See more : Metro Performance Glass Limited (MPP.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Novo Nordisk A/S (NVO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Novo Nordisk A/S, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- US Financial 15 Split Corp (FTU-PB.TO) Income Statement Analysis – Financial Results
- Three Sixty Solar Ltd. (VSOL.NE) Income Statement Analysis – Financial Results
- Primorus Investments plc (PRIM.L) Income Statement Analysis – Financial Results
- Federal National Mortgage Association (FNMA) Income Statement Analysis – Financial Results
- Aladdin Healthcare Technologies SE (ALDNF) Income Statement Analysis – Financial Results
Novo Nordisk A/S (NVO)
About Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 232.26B | 176.95B | 140.80B | 126.95B | 122.02B | 111.83B | 111.70B | 111.78B | 107.93B | 88.81B | 83.57B | 78.03B | 66.35B | 60.78B | 51.08B | 45.67B | 41.89B | 38.75B | 33.71B | 29.23B | 26.61B | 25.15B | 23.72B | 20.82B | 20.94B | 17.91B | 16.98B | 14.90B | 13.71B | 13.52B | 13.15B | 10.67B | 9.83B | 8.33B | 7.62B | 5.63B | 5.03B | 4.19B | 4.16B |
| Cost of Revenue | 35.77B | 28.45B | 23.66B | 20.93B | 20.09B | 17.62B | 17.63B | 17.18B | 16.19B | 14.56B | 14.14B | 13.47B | 12.59B | 11.68B | 10.44B | 10.13B | 9.80B | 9.59B | 9.17B | 8.11B | 7.46B | 6.62B | 5.96B | 4.38B | 5.05B | 4.39B | 4.72B | 4.17B | 3.83B | 3.83B | 6.41B | 2.53B | 4.80B | 4.13B | 3.76B | 2.72B | 2.59B | 3.29B | 2.07B |
| Gross Profit | 196.50B | 148.51B | 117.14B | 106.01B | 101.93B | 94.21B | 94.06B | 94.60B | 91.74B | 74.24B | 69.43B | 64.56B | 53.76B | 49.10B | 40.64B | 35.53B | 32.09B | 29.16B | 24.55B | 21.13B | 19.15B | 18.53B | 17.75B | 16.44B | 15.89B | 13.52B | 12.26B | 10.74B | 9.88B | 9.68B | 6.74B | 8.14B | 5.03B | 4.21B | 3.85B | 2.91B | 2.44B | 893.58M | 2.09B |
| Gross Profit Ratio | 84.60% | 83.92% | 83.20% | 83.51% | 83.54% | 84.25% | 84.21% | 84.63% | 85.00% | 83.60% | 83.08% | 82.74% | 81.03% | 80.78% | 79.56% | 77.81% | 76.60% | 75.26% | 72.81% | 72.27% | 71.96% | 73.66% | 74.85% | 78.96% | 75.89% | 75.50% | 72.20% | 72.04% | 72.07% | 71.64% | 51.26% | 76.32% | 51.22% | 50.49% | 50.59% | 51.75% | 48.49% | 21.34% | 50.14% |
| Research & Development | 32.44B | 24.05B | 17.77B | 15.46B | 14.22B | 14.81B | 14.01B | 14.56B | 13.61B | 13.76B | 11.73B | 10.90B | 9.63B | 9.60B | 7.86B | 7.87B | 8.55B | 6.32B | 5.07B | 4.38B | 4.20B | 4.13B | 3.96B | 3.22B | 3.36B | 3.40B | 2.77B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 4.86B | 4.47B | 4.05B | 3.96B | 4.01B | 3.92B | 3.78B | 3.96B | 3.86B | 3.54B | 3.51B | 3.31B | 3.25B | 3.72B | 2.76B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 56.74B | 46.22B | 37.01B | 32.93B | 31.82B | 29.40B | 28.34B | 28.38B | 28.31B | 23.22B | 23.38B | 21.54B | 19.00B | 18.20B | 15.42B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 61.60B | 50.68B | 41.06B | 36.89B | 35.83B | 33.31B | 32.12B | 32.34B | 32.17B | 26.76B | 26.89B | 24.86B | 22.25B | 21.92B | 18.18B | 15.82B | 14.90B | 14.00B | 11.79B | 10.30B | 9.67B | 9.42B | 9.06B | 7.93B | 7.50B | 6.59B | 6.02B | 7.69B | 6.87B | 6.79B | 3.99B | 6.29B | 3.04B | 2.63B | 2.33B | 1.65B | 1.52B | 0.00 | 1.15B |
| Other Expenses | -119.00M | -1.03B | -332.00M | -460.00M | -600.00M | -1.15B | -1.04B | -737.00M | -3.48B | -770.00M | -682.00M | -666.00M | 0.00 | 0.00 | 0.00 | -572.36M | -322.18M | -271.23M | -397.15M | -581.71M | -1.12B | -997.95M | -860.46M | 1.03B | 1.43B | 1.47B | 1.14B | 1.07B | 1.14B | 1.06B | 799.09M | 693.74M | 591.94M | 520.42M | 471.78M | 323.77M | 266.42M | 224.68M | 199.90M |
| Operating Expenses | 93.92B | 73.70B | 58.50B | 51.89B | 49.45B | 46.97B | 45.10B | 46.17B | 42.30B | 39.75B | 37.94B | 35.09B | 31.88B | 31.52B | 26.05B | 23.12B | 23.13B | 20.04B | 16.47B | 14.10B | 12.75B | 12.56B | 12.16B | 12.19B | 12.28B | 11.46B | 9.93B | 8.76B | 8.01B | 7.84B | 4.79B | 6.99B | 3.63B | 3.15B | 2.80B | 1.98B | 1.79B | 224.68M | 1.35B |
| Cost & Expenses | 129.69B | 102.15B | 82.16B | 72.82B | 69.54B | 64.58B | 62.73B | 63.35B | 58.48B | 54.31B | 52.08B | 48.55B | 44.47B | 43.20B | 36.49B | 33.26B | 32.93B | 29.63B | 25.64B | 22.20B | 20.22B | 19.18B | 18.12B | 16.57B | 17.33B | 15.84B | 14.65B | 12.92B | 11.84B | 11.68B | 11.20B | 9.51B | 8.43B | 7.28B | 6.57B | 4.69B | 4.38B | 3.52B | 3.43B |
| Interest Income | 1.07B | 239.00M | 2.89B | 337.00M | 65.00M | 51.00M | 69.00M | 52.00M | 85.00M | 167.00M | 56.00M | 125.00M | 514.00M | 382.00M | 375.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 739.00M | 378.00M | 2.45B | 390.00M | 220.00M | 85.00M | 90.00M | 65.00M | 6.05B | 563.00M | 55.00M | 1.79B | 959.00M | 2.06B | 1.27B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 9.41B | 6.60B | 5.31B | 5.28B | 4.68B | 3.81B | 2.87B | 2.65B | 3.04B | 3.60B | 3.57B | 2.82B | 20.00M | 2.85B | 3.27B | 2.08B | 1.90B | 1.64B | 1.21B | 1.44B | 1.63B | 1.33B | 208.85M | 665.76M | 1.19B | 1.47B | 1.14B | 1.07B | 1.14B | 1.06B | 799.09M | 693.74M | 591.94M | 520.42M | 471.78M | 323.77M | 266.42M | 224.68M | 199.90M |
| EBITDA | 113.33B | 76.41B | 64.83B | 58.57B | 56.31B | 51.57B | 51.69B | 50.58B | 49.58B | 38.09B | 35.25B | 30.44B | 24.94B | 21.25B | 17.80B | 14.48B | 11.97B | 10.76B | 9.29B | 8.47B | 8.02B | 6.05B | 5.81B | 4.91B | 4.81B | 2.09B | 2.31B | 2.15B | 2.61B | 2.42B | 2.26B | 812.29M | 1.54B | 1.19B | 1.27B | 1.02B | 708.41M | 675.51M | 673.20M |
| EBITDA Ratio | 48.79% | 46.36% | 47.98% | 47.43% | 47.36% | 45.75% | 46.70% | 46.18% | 48.63% | 42.90% | 41.95% | 41.39% | 33.75% | 35.77% | 35.63% | 31.71% | 25.91% | 27.76% | 27.54% | 28.98% | 22.57% | 24.06% | 24.48% | 23.58% | 22.94% | 11.68% | 13.59% | 14.45% | 19.05% | 17.91% | 17.22% | 7.61% | 15.70% | 14.23% | 16.61% | 18.05% | 14.09% | 16.13% | 16.19% |
| Operating Income | 102.57B | 74.81B | 58.64B | 54.13B | 52.48B | 47.25B | 48.97B | 48.43B | 49.44B | 34.49B | 31.49B | 29.47B | 22.37B | 18.89B | 14.93B | 12.40B | 8.95B | 9.12B | 8.08B | 7.03B | 4.38B | 4.72B | 5.60B | 4.24B | 3.62B | 623.53M | 1.17B | 1.09B | 1.47B | 1.37B | 1.47B | 118.55M | 950.89M | 664.82M | 793.56M | 692.21M | 442.00M | 450.83M | 473.30M |
| Operating Income Ratio | 44.16% | 42.28% | 41.65% | 42.64% | 43.01% | 42.25% | 43.84% | 43.33% | 45.81% | 38.84% | 37.68% | 37.77% | 33.72% | 31.08% | 29.24% | 27.16% | 21.38% | 23.53% | 23.95% | 24.05% | 16.46% | 18.77% | 23.60% | 20.39% | 17.26% | 3.48% | 6.86% | 7.29% | 10.74% | 10.10% | 11.14% | 1.11% | 9.67% | 7.98% | 10.42% | 12.30% | 8.79% | 10.77% | 11.38% |
| Total Other Income/Expenses | 2.10B | -5.75B | 436.00M | -996.00M | -3.93B | 367.00M | -287.00M | -634.00M | -5.96B | -396.00M | 1.05B | -1.66B | -449.00M | -605.00M | -945.00M | 320.95M | 2.03B | 45.20M | 144.99M | 477.44M | 1.18B | 1.57B | 417.70M | 601.59M | 340.08M | 3.12B | 2.01B | 1.44B | 681.11M | 565.52M | 407.02M | 1.55B | 511.52M | 473.05M | 255.71M | 213.09M | 255.44M | 337.76M | 403.38M |
| Income Before Tax | 104.67B | 69.06B | 59.08B | 53.13B | 48.55B | 47.62B | 48.68B | 47.80B | 43.48B | 34.10B | 32.54B | 27.81B | 21.93B | 18.29B | 13.99B | 12.73B | 10.98B | 9.17B | 8.22B | 7.51B | 7.58B | 6.29B | 6.01B | 4.84B | 3.96B | 3.75B | 3.17B | 2.53B | 2.15B | 1.93B | 1.87B | 1.67B | 1.46B | 1.14B | 1.05B | 905.31M | 697.44M | 788.58M | 876.68M |
| Income Before Tax Ratio | 45.07% | 39.03% | 41.96% | 41.85% | 39.79% | 42.58% | 43.58% | 42.76% | 40.29% | 38.39% | 38.94% | 35.64% | 33.05% | 30.09% | 27.39% | 27.87% | 26.22% | 23.65% | 24.38% | 25.68% | 28.48% | 25.01% | 25.36% | 23.28% | 18.88% | 20.91% | 18.67% | 16.97% | 15.71% | 14.29% | 14.24% | 15.68% | 14.88% | 13.66% | 13.77% | 16.08% | 13.87% | 18.83% | 21.08% |
| Income Tax Expense | 20.99B | 13.54B | 11.32B | 10.99B | 9.60B | 8.99B | 10.55B | 9.87B | 8.62B | 7.62B | 7.36B | 6.38B | 4.83B | 3.88B | 3.22B | 3.06B | 2.45B | 2.71B | 2.36B | 2.46B | 2.53B | 2.20B | 2.16B | 1.76B | 1.55B | 1.34B | 952.42M | 726.73M | 592.44M | 499.85M | 441.68M | 400.19M | 532.22M | 377.75M | 303.28M | 267.40M | 217.04M | 267.27M | 268.92M |
| Net Income | 83.68B | 55.53B | 47.76B | 42.14B | 38.95B | 38.63B | 38.13B | 37.93B | 34.86B | 26.48B | 25.18B | 21.43B | 17.10B | 14.40B | 10.77B | 9.67B | 8.54B | 6.45B | 5.86B | 5.05B | 4.87B | 4.09B | 3.85B | 3.09B | 2.41B | 2.41B | 2.22B | 1.80B | 1.56B | 1.43B | 1.43B | 1.27B | 930.19M | 760.12M | 745.99M | 637.91M | 480.40M | 521.32M | 607.76M |
| Net Income Ratio | 36.03% | 31.38% | 33.92% | 33.19% | 31.92% | 34.54% | 34.14% | 33.93% | 32.30% | 29.82% | 30.13% | 27.47% | 25.77% | 23.70% | 21.08% | 21.17% | 20.38% | 16.65% | 17.37% | 17.27% | 18.31% | 16.26% | 16.24% | 14.84% | 11.51% | 13.45% | 13.07% | 12.09% | 11.39% | 10.59% | 10.88% | 11.93% | 9.46% | 9.12% | 9.79% | 11.33% | 9.55% | 12.45% | 14.62% |
| EPS | 9.34 | 12.26 | 10.40 | 9.03 | 4.10 | 3.99 | 7.71 | 7.50 | 6.78 | 5.05 | 4.70 | 7.82 | 3.03 | 2.48 | 1.80 | 1.57 | 1.36 | 1.01 | 0.89 | 0.75 | 0.72 | 0.59 | 0.56 | 0.45 | 0.35 | 0.26 | 0.30 | 0.24 | 0.21 | 0.19 | 0.19 | 0.17 | 0.16 | 0.12 | 0.10 | 0.13 | 0.10 | 0.11 | 0.12 |
| EPS Diluted | 9.31 | 12.22 | 10.37 | 9.01 | 4.10 | 3.99 | 7.70 | 7.48 | 6.76 | 5.04 | 4.68 | 7.77 | 3.00 | 2.46 | 1.78 | 1.55 | 1.35 | 1.00 | 0.89 | 0.75 | 0.71 | 0.59 | 0.56 | 0.45 | 0.34 | 0.26 | 0.30 | 0.24 | 0.21 | 0.19 | 0.19 | 0.17 | 0.16 | 0.12 | 0.10 | 0.13 | 0.10 | 0.11 | 0.12 |
| Weighted Avg Shares Out | 4.48B | 4.53B | 4.59B | 4.67B | 4.75B | 4.84B | 4.96B | 5.07B | 5.16B | 5.26B | 5.39B | 5.52B | 5.65B | 5.81B | 5.99B | 3.09B | 3.15B | 3.21B | 3.28B | 3.38B | 3.42B | 3.46B | 3.44B | 3.46B | 3.80B | 3.80B | 3.77B | 3.74B | 3.76B | 3.74B | 3.76B | 3.76B | 5.83B | 3.13B | 4.03B | 5.16B | 5.08B | 5.07B | 5.02B |
| Weighted Avg Shares Out (Dil) | 4.49B | 4.54B | 4.61B | 4.68B | 4.76B | 4.85B | 4.96B | 5.07B | 5.16B | 5.26B | 5.39B | 5.52B | 5.70B | 5.85B | 6.04B | 3.11B | 3.18B | 3.23B | 3.29B | 3.39B | 3.44B | 3.49B | 3.47B | 3.47B | 3.80B | 3.80B | 3.77B | 3.74B | 3.76B | 3.74B | 3.76B | 3.76B | 5.83B | 3.13B | 4.03B | 5.16B | 5.08B | 5.07B | 5.02B |
Is Novo Nordisk Stock a Buy Right Now?
Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 19 November 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market...
Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). A...
Medicaid dominates coverage of Novo, Lilly weight-loss drugs
U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the reimbursement available from private employers and insurers, according to an analysis shared with Reuters.
Novo Nordisk launches Wegovy weight drug in China at fraction of price
Novo Nordisk (NYSE:NVO) has begun rolling out its Wegovy weight loss drug in China at well below the price of the product in the US. A month's supply of the starter dose of Wegovy in China has been priced at...
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 18 November 2024 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission...
Novo Nordisk has launched obesity drug Wegovy in China
Novo Nordisk said on Monday it has launched its popular obesity drug Wegovy in China, the world's second-largest pharmaceuticals market.
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
Eli Lilly and Novo Want to Shake off Ozempic Copycats. Are They Ready To Meet Demand?
The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it's unclear whether they can ramp up production enough.
Vaccine Maker Stocks Slump After RFK Jr. Nominated as HHS Head
In the 2024 presidential election's latest impact on the stock markets, shares of several vaccine makers were down Friday morning following the nomination of Robert F. Kennedy Jr. to head the Department of Health and Human Services.
Source: https://incomestatements.info
Category: Stock Reports